Therefore, the analysis of CTLs as well as B7‐1 status in primary tumor tissues could provide further information as to the necessity of evaluating PD‐L1 status in metastasis or liquid biopsy when applicable in order to improve the therapeutic efficacy of PD‐1/PD‐L1 inhibitors in NSCLC patients. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.